KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

摘要: Background: KRAS mutation status is a candidate marker for predicting survival in patients with metastatic colorectal cancer (mCRC) treated cetuximab (CTX). Patients and methods: We studied the of 113 irinotecan refractory mCRC CTX clinical trials. A predictive model objective response (OR), progression-free (PFS) overall (OS) was constructed using logistic Cox regression. Results: OR seen 27 66 wild-type (WT) versus 0 42 mutants. Median OS significantly better WT mutants (43.0 27.3 weeks; P = 0.020). Decrease tumor sizes larger at all time points patients. an initial relative decrease size > 9.66% week 6 had median compared other (74.9 30.6 0.0000025). Within those without [median OS: 74.9 weeks (P 0.00000012)]. Conclusions: associated to benefit mCRC. This even more pronounced early radiological response. These characteristics may be exploited prediction.